Lincoln Pharmaceuticals Q3 FY24 Results Live: Profit Rises by 29.74% YoY
Lincoln Pharmaceuticals declared their Q3 FY24 results on 08 Feb, 2024. The topline increased by 9.48% & the profit increased by 29.74% YoY. As compared to the previous quarter, the revenue declined by 6.11% and the profit increased by 1.4%.
The Selling, general & administrative expenses rose by 6% q-o-q & increased by 12.78% Y-o-Y.
The operating income was down by 6.02% q-o-q & increased by 9.63% Y-o-Y.
The EPS is ₹14 for Q3 FY24 which increased by 29.75% Y-o-Y.
Lincoln Pharmaceuticals has delivered 1.76% return in the last 1 week, 34.49% return in the last 6 months and 8% YTD return.
Currently, Lincoln Pharmaceuticals has a market cap of ₹1318.46 Cr and 52wk high/low of ₹714.95 & ₹317 respectively.
| Period | Q3 FY24 | Q2 FY24 | Q-o-Q Growth | Q3 FY23 | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 146.45 | 155.99 | -6.11% | 133.77 | +9.48% |
| Selling/ General/ Admin Expenses Total | 26.44 | 24.94 | +6% | 23.44 | +12.78% |
| Depreciation/ Amortization | 2.81 | 2.58 | +9.07% | 2.26 | +24.39% |
| Total Operating Expense | 119.6 | 127.42 | -6.14% | 109.28 | +9.45% |
| Operating Income | 26.85 | 28.57 | -6.02% | 24.49 | +9.63% |
| Net Income Before Taxes | 37.71 | 36.87 | +2.28% | 30.51 | +23.58% |
| Net Income | 28.04 | 27.65 | +1.4% | 21.61 | +29.74% |
| Diluted Normalized EPS | 14 | 13.81 | +1.38% | 10.79 | +29.75% |
FAQs
Question : What is the Q3 FY24 profit/Loss as per company?
Ans : ₹28.04Cr
Question : What is Q3 FY24 revenue?
Ans : ₹146.45Cr
Stay updated on quarterly results with our results calendar
Here’s your comprehensive 3-minute summary of all the things Finance Minister Nirmala Sitharaman said in her Budget speech: Click to download!
Download Finplay News App to get Daily Market Updates & Live Business News.
More
Less
Published: 10 Feb 2024, 03:44 AM IST
Ganesh
http://ganesh@finplay.inFinance enthusiast, Mutual fund expert.